Abstract:
Background: One of the most important tuberculosis control action represents the effective anti-tuberculosis treatment. The standard regimens are associated with high level of side effects, especially at patients with hepatobiliary and pancreatic co-morbidities. Material and methods: There were studied clinical and laboratory indices of a total number of 60 new pulmonary tuberculosis cases, with proved hepatobiliary and pancreatic comorbidities, distributed in the 1st study group, consisted of 30 patients treated with the standard anti-tuberculosis treatment, all drugs being administrated orally and the 2nd control group, consisted of 30 patients, treated with the standard anti-tuberculosis treatment with injected forms of first line anti-tuberculosis drugs isoniazid and rifampicin. Results: The clinical improvement of the patient’s general state under the influence of intravenous use of isoniazid and rifampicin was confirmed by a lower expressiveness of intoxication and bronchopulmonary syndroms, as well as by a better radiological dynamics and higher rate of microscopic convertion at the end of intensive phase of the tuberculosis treatment. Biochemical disturbances due to tuberculosis treatment were less evident at the patients treated with intravenous isoniazid and rifampicin, confirmed by a better rehabilitation of mathematic indices of endogenous intoxication. Conclusions: Assessing the differences between the clinical and laboratory tolerance of tuberculosis drugs according to the way of administration, it was proved the importance of individualization of the standard treatment at patients with hepatobiliary and pancreatic disorders by intravenous use of isoniazid and rifampicin in intensive phase of the treatment, for improving the therapeutical effectiveness.
